AstraZeneca Wields Amarin Win In FDA Exclusivity Fight

Law360, New York (November 4, 2015, 5:03 PM EST) -- AstraZeneca is wielding a recent court victory by Amarin Pharma in hopes of securing longer exclusivity for triglyceride-reducing drug Epanova, a sign that the ruling carries significant implications for new products with older components.

The U.K. drugmaker's action came Monday in a supplement to a citizen petition it lodged last year with the U.S. Food and Drug Administration. The supplement focused on a May court ruling that vacated the FDA's denial of five-year exclusivity for Amarin Pharmaceuticals Ireland Ltd.'s omega-3 drug Vascepa.

According to AstraZeneca LP, the ruling "firmly supports" its request that the FDA grant five-year exclusivity to Epanova. The...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!